Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
19.81B
Market cap19.81B
Price-Earnings ratio
-6.13
Price-Earnings ratio-6.13
Dividend yield
Dividend yield
Average volume
5.62M
Average volume5.62M
High today
$51.74
High today$51.74
Low today
$49.26
Low today$49.26
Open price
$49.98
Open price$49.98
Volume
5.08M
Volume5.08M
52 Week high
$59.55
52 Week high$59.55
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

With a market cap of 19.81B, Moderna(MRNA) trades at $49.87. The stock has a price-to-earnings ratio of -6.13.

On 2026-06-12, Moderna(MRNA) stock traded between a low of $49.26 and a high of $51.74. Shares are currently priced at $49.87, which is +1.2% above the low and -3.6% below the high.

Moderna(MRNA) shares are trading with a volume of 5.08M, against a daily average of 5.62M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $59.55 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $59.55 and a 52-week low of $22.28.

MRNA News

Nasdaq 16h
Moderna Reaches Analyst Target Price

In recent trading, shares of Moderna Inc (Symbol: MRNA) have crossed above the average analyst 12-month target price of $46.62, changing hands for $49.70/share....

Moderna Reaches Analyst Target Price
TipRanks 2d
Moderna’s Maternal RSV Vaccine Study Reaches Completion: What Investors Should Watch

Moderna (MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. (MRNA) is running a Phase 2 trial called “A Study of mRNA-1345 Vaccine Targ...

Simply Wall St 3d
Moderna Moves Into Cancer Prevention With UK Lynch Syndrome Trial

UK regulators have authorized a Phase 1/2 trial of Moderna and Oxford's mRNA-4194 preventive cancer vaccine for people with Lynch Syndrome. The first-in-human...

Moderna Moves Into Cancer Prevention With UK Lynch Syndrome Trial

Analyst ratings

63%

of 27 ratings
Buy
18.5%
Hold
63%
Sell
18.5%

More MRNA News

Nasdaq 4d
Does Moderna Need to Start Making Money?

Key Points Moderna is losing billions of dollars per year. The company has several promising new products that should be coming to the market within the next...

Does Moderna Need to Start Making Money?
TipRanks 5d
Moderna price target raised to $34 from $32 at BofA

BofA raised the firm’s price target on Moderna (MRNA) to $34 from $32 and keeps an Underperform rating on the shares after having hosted Moderna’s CEO for a gro...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.